Table 2.

Effects of antagonist and enzyme inhibitors on anandamide and HU210-mediated relaxation in rat CA

	pEC50	Rmax	n
Anandamide	−7.63 ± 0.30	38.92 ± 4.93	6
Anandamide + AM251 (10 µM)	−7.73 ± 0.33	41.71 ± 6.01	6
Anandamide	−8.01 ± 0.33	35.41 ± 2.85	6
Anandamide + AM630 (100 nM)	−7.39 ± 0.37*	25.56 ± 2.88*	5
Anandamide	−7.72 ± 0.29	38.92 ± 3.77	6
Anandamide + AM630 (10 µM)	−7.60 ± 0.46	24.99 ± 2.78*	6
Anandamide	−7.65 ± 0.29	41.09 ± 3.45	7
Anandamide + JTE907	−8.24 ± 0.42	9.724 ± 0.92*	5
Anandamide (denuded)	−7.48 ± 0.24	41.36 ± 3.17	6
Anandamide + AM630 (10 µM) (denuded)	−6.95 ± 0.23	44.55 ± 4.24	4
HU210	−7.40 ± 0.5	31.03 ± 4.44	5
HU210 + AM251 (10 µM)	−7.87 ± 0.69	25.51 ± 4.636	6
HU210	−7.40 ± 0.5	31.03 ± 4.44	5
#HU210 + AM630 (10 µM)	−5.72 ± 1.19#	14.71 ± 13.81#	4
Anandamide	−7.53 ± 0.35	47.50 ± 5.37	13
Anandamide + indomethacin (10 µM)	−8.41 ± 0.43	22.50 ± 1.93*	7
Anandamide (denuded)	−7.51 ± 0.54	49.12 ± 7.32	7
Anandamide + indomethacin (10 µM) (denuded)	−7.54 ± 0.37	46.50 ± 5.73	6
Anandamide	−7.63 ± 0.30	38.92 ± 3.38	13
Anandamide + SKi (10 µM)	NA	2.3 ± 6.16*	5
Anandamide (denuded)	−7.59 ± 0.28	40.08 ± 3.28	6
Anandamide + SKi (10 µM) (denuded)	−7.188 ± 0.36	37.57 ± 5.10	4
Anandamide	−7.63 ± 0.28	38.92 ± 5.37	13
Anandamide + VPC23019 (10 µM)	−7.57 ± 0.35	14.85 ± 1.36*	8
Anandamide (denuded)	−7.65 ± 0.25	40.19 ± 2.86	7
Anandamide + VPC23019 (10 µM) (denuded)	−7.175 ± 0.21	36.74 ± 2.24	8
Anandamide	−7.63 ± 0.3	38.92 ± 5.37	13
Anandamide + W146 (10 µM)	−7.04 ± 0.28	34.76 ± 3.08	5
Anandamide	−7.63 ± 0.3	38.92 ± 5.37	13
Anandamide + CAY10444 (10 µM)	−7.99 ± 0.28	16.15 ± 2.90*	5
Anandamide (denuded)	−7.65 ± 0.25	40.19 ± 2.86	7
Anandamide + CAY10444 (denuded) (10 µM)	−7.33 ± 0.26	47.33 ± 3.32	6
Anandamide	−7.63 ± 0.29	38.92 ± 3.37	6
Anandamide + AM630 (100 nM) + CAY10444 (10 µM)	−6.76 ± 0.32*	25.51 ± 3.50*	4

Data are expressed as mean ± SEM for n arteries from different animals.

^*P < 0.05 versus anandamide alone,

^#P < 0.05 versus HU210 alone as determined by two-way anova.